IQVIA Holdings Inc. (IQV) Cash Flow Statement

The persistent gap between net income and operating cash flow, driven by large D&A charges (averaging ~$280M per quarter) and modest working capital swings, suggests that reported earnings understate the company's cash-generating ability. However, the 2025Q4 spike in OCF/NI to 2.74x, aided by a $452M working capital inflow, appears anomalous and may not be sustainable. Investors should monitor whether the gap narrows as amortization from past acquisitions eventually declines.

The extreme quarterly volatility in FCF margins, driven by working capital swings and a one-off $293M capex inflow in 2025Q4, obscures a stable underlying trend. Excluding that quarter, FCF margins have hovered between 7% and 18%, consistent with a capital-intensive services model. The recent dip to 8.2% in 2026Q2, despite revenue growth, suggests that cash conversion may be temporarily pressured by project timing and client payment patterns.

The consistent capex intensity, averaging around 3.9% of revenue, suggests that IQV's growth does not require heavy capital reinvestment, freeing up cash for debt reduction and buybacks. The 2025Q4 positive capex of $293M is a clear data anomaly, likely reflecting a sale-leaseback or asset disposal, and should be disregarded for trend analysis. This moderate capital expenditure supports the view that IQV's data and analytics moat is more intellectual than physical.

The erratic working capital movements, particularly the $452M inflow in 2025Q4, appear tied to the timing of clinical trial milestones and collections, rather than a systemic issue. The negative changes in 2026Q2 (-$34M) and 2025Q2 (-$104M) suggest that cash outflows for receivables or inventory can temporarily outpace inflows. Investors should monitor days sales outstanding (DSO) trends to ensure that revenue growth is translating into cash collections without elongating the cycle.

The substantial buyback activity, including $1.1B in 2024Q4 and $552M in 2026Q1, indicates management's confidence in the stock and a commitment to returning capital, despite the elevated leverage. However, the consistent acquisition outflows, averaging ~$250M per quarter, suggest that M&A remains a core part of the growth strategy, potentially limiting the pace of deleveraging. Given the net debt-to-EBITDA of ~4.9x, investors should assess whether this capital allocation mix is sustainable without straining the balance sheet.

The cumulative gap of $3.2B between operating cash flow and net income underscores the impact of high amortization from past acquisitions, which is a non-cash expense. This divergence suggests that IQV's true economic earnings power is stronger than GAAP net income implies, but it also raises questions about the sustainability of the gap as amortization eventually declines. The consistent OCF/NI ratio above 1.4x in most quarters indicates that cash conversion is structurally robust, not just a one-time phenomenon.